IBB News and Press, iShares Biotechnology ETF From 01/20/23

Summary CTI BioPharma has reported a better-than-expected Q3 print of 18.5M, which is a 40% growth QoQ, and we expect this growth to continue reaching close to USD60M in FY2022. CTIC’s Vonjo (Pacritinib) is a differentiated late-stage JAK2/IRAK4/FLT3/CSF1R inhibitor for the treat...

Summary Last year’s market volatility was driven primarily by uncertainty over inflation and interest rates. In last year’s downturn, technology stocks were at the epicenter of market volatility. After years of steady gains, investors now acknowledge that technology stocks...

Summary Pharmaceuticals and biotechnology have the best value and quality scores in the sector. Healthcare providers are close to their historical baseline in valuation and quality. Fast facts on GNOM. 10 stocks cheaper than their peers in January. This monthly article...

Summary Vera’s phase 2b ORIGIN data was underwhelming with lower than expected proteinuria reduction ~31% even at 9 months. We believe Atacicept’s commercial opportunity in IgAN is questionable due to the high degree of competition from KDNY, Otsuka, and Remegen. VERA ...

Summary iShares Biotechnology has outperformed the S&P 500 during all 3 recessions in the U.S. since inception in early 2001. Healthcare and pharmaceutical shares have a strong track record of holding up during bear markets and recessions over the last 100 years. The Top 10 hold...

Summary Healthcare stocks have remained in vogue through volatile markets, driven by increased interest in the sector during COVID-19. During a painful year for equity investors in 2022, healthcare stocks offered a pocket of relative stability. Global healthcare stocks ended the yea...

Summary How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector. How staff shortages in the health care sector may also impact investors. Health care managed to outperform the S&P 500 last yea...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...

Summary The technology sector is highly cyclical and sensitive to interest rates, and the valuation for many companies is still overvalued; tech should continue to get clobbered during 2023. Inflation is still high; the fed is still hiking rates; the yield curve is still inverted, and m...

Summary Scynexis has performed terribly during 2022 due to continued disappointment in earnings and sales ramp. New labels, including black-boxed warnings, could further hamper the slow commercial adoption of VVC indication, especially in the retail setting. We do not believe rVVC w...